It helps to think of direct-to-consumer products as sitting on a spectrum, from reasonably reliable for their stated purpose to poorly supported by evidence.

• Ancestry and geographic origin. These estimates use large reference databases of population genetic variation and are generally reasonable for their intended purpose, though the precision of a breakdown, especially for South Asian sub-regions, is limited by how well those specific populations are represented in the company’s reference data.
• A small number of well-studied, high-impact variants. A handful of direct-to-consumer products, most notably certain authorized versions of major United States-based kits, report on specific, thoroughly validated disease-linked changes, such as three particular BRCA1 and BRCA2 variants common in one specific ancestral population, or a small set of variants linked to certain other adult-onset conditions. Where these exist, they can be a reasonable first flag, but a positive result still requires confirmation through accredited clinical testing before any medical decision is made, and a negative result covers only those specific variants, not the gene as a whole.
• Polygenic risk scores for common conditions. These combine the small individual effects of many genetic variants to estimate a relative risk for conditions such as heart disease, type 2 diabetes, or certain cancers. They are an active area of research but are not currently considered reliable enough, especially outside the population groups they were built on, to guide individual medical decisions on their own.
• Carrier status for recessive conditions. Some kits screen for carrier status in a limited panel of conditions. Unlike a clinical carrier screening panel chosen with a genetic counselor to match a person’s ethnic background, family history, and reproductive plans, a direct-to-consumer panel is fixed and may miss conditions that are actually most relevant to a particular family.
• Wellness, nutrition, fitness, and supplement recommendations. This category has the weakest scientific support of all direct-to-consumer offerings. Professional genetics organizations, including the Indian Academy of Medical Genetics, have specifically cautioned that clinical utility for these products has not been established, and they should not be used to guide medical, dietary, or supplement decisions.

What direct-to-consumer testing cannot do, regardless of category, is replace a structured clinical evaluation for a person or family with a specific medical concern, such as a strong family history of a particular cancer, a child with unexplained developmental delay, or a couple planning a pregnancy with a known genetic condition in the family. Those situations call for testing chosen and interpreted by a genetics professional, using a laboratory equipped to look at the entire relevant gene, not a fixed consumer panel.